Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT ID: NCT03539536

Last Updated: 2025-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

270 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-10

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telisotuzumab vedotin

Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.

Group Type EXPERIMENTAL

Telisotuzumab vedotin

Intervention Type DRUG

Intravenous (IV) infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telisotuzumab vedotin

Intravenous (IV) infusion

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABBV-399

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have locally advanced or metastatic non-small cell lung cancer (NSCLC).
* Have c-Met+ NSCLC as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory. Participant must submit archival or fresh tumor material for assessment of c-Met levels during the prescreening period. Tumor material from the primary tumor site and/or metastatic sites are allowed. If archival tissue is negative for c-Met overexpression, subject can submit fresh biopsy material for reassessment of c-Met expression.
* Histologically documented non-squamous epidermal growth factor receptor (EGFR) wild type NSCLC (site documented EGFR status). Of note, subjects with other actionable mutations are eligible as long as EGFR status is known and all other eligibility criteria are met. As of Protocol Version 11, Stage 1 is complete and Stage 2 is enrolling participants with non-squamous EGFR wild type NSCLC only.
* Must have received no more than 2 lines of prior systemic therapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the locally advanced or metastatic setting.
* Multiple lines of tyrosine kinase inhibitors (TKIs) targeting the same tyrosine kinase (TK) count as 1 line of therapy for the purposes of this eligibility criterion.
* Progressed on systemic cytotoxic therapy (or are ineligible for systemic cytotoxic chemotherapy) and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible), and prior anticancer therapies targeting driver gene alterations (if applicable).
* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
* Treatment with any therapies within the noted time intervals is excluded prior to the first dose of telisotuzumab vedotin as noted in the protocol.
* Metastases to the central nervous system (CNS) are eligible only after definitive therapy (such as surgery or radiotherapy) is provided within the protocol.

Exclusion Criteria

* Have received radiation therapy to the lungs \< 6 months prior to the first dose of telisotuzumab vedotin.
* Have received any live vaccine within 30 days of the first dose of investigational product.
* Has adenosquamous histology.
* Have a history of other malignancies except those noted within the protocol.
* Have a history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids.
* Have any evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or ILD within 3 months of the planned first dose of the study drug (Except for Sites in Ireland). For imaging findings deemed clinically insignificant by the treating physician, subject may be eligible after discussion with and approval from the AbbVie medical monitor.
* For Sites in Ireland Only: Must not have any evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or ILD. For imaging findings deemed clinically insignificant by the treating physician, subject may be eligible after discussion with and approval from the AbbVie medical monitor.
* Have a clinically significant condition(s) as noted in the protocol.
* Have unresolved clinically significant adverse events of Grade \>= 2 from prior anticancer therapy, except for alopecia or anemia.
* Have had major surgery within 21 days prior to the first dose of telisotuzumab vedotin.
* For Sites in France and Czech Republic Only: Have the following:

* Known human immunodeficiency virus (HIV) infection. Note: HIV testing is not required for eligibility for this protocol unless mandated by local regulatory authority or ethics committee/institutional review board.
* Active hepatitis B virus (HBV) infection, defined by hepatitis B surface antigen (HBsAg) positivity or HBV DNA \>= 500 IU/mL. In participants with known HBV infection, the presence of active infection must be tested locally. If HBV status is unknown, it must be tested locally at screening.
* Active hepatitis C virus (HCV) infection, defined by HCV ribonucleic acid (RNA) positivity. Participants cured of HCV infection may be included in the study. In participants with known HCV infection, the presence of active infection must be tested locally. If HCV status is unknown, it must be tested locally at screening.
* Uncontrolled autoimmune disease.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of South Alabama /ID# 212939

Mobile, Alabama, United States

Site Status

Mayo Clinic Arizona /ID# 218550

Phoenix, Arizona, United States

Site Status

Highlands Oncology Group, PA /ID# 215600

Springdale, Arkansas, United States

Site Status

University of California, Los Angeles /ID# 203219

Los Angeles, California, United States

Site Status

LA Hematology-Oncology Med Group /ID# 203338

Orange, California, United States

Site Status

Sutter Medical Center Sacramen /ID# 203299

Sacramento, California, United States

Site Status

Icri /Id# 227835

Whittier, California, United States

Site Status

Univ of Colorado Cancer Center /ID# 203212

Aurora, Colorado, United States

Site Status

Duplicate_Rocky Mountain Cancer Centers - Lone Tree /ID# 215789

Lone Tree, Colorado, United States

Site Status

Advanced Cancer Treatment Center /ID# 239565

Brooksville, Florida, United States

Site Status

AdventHealth Celebration /ID# 215649

Celebration, Florida, United States

Site Status

Duplicate_Mayo Clinic /ID# 218488

Jacksonville, Florida, United States

Site Status

Duplicate_AdventHealth Cancer Institute - Orlando /ID# 239960

Orlando, Florida, United States

Site Status

Straub Clinic and Hospital /ID# 217905

Honolulu, Hawaii, United States

Site Status

Northwestern University Feinberg School of Medicine /ID# 203239

Chicago, Illinois, United States

Site Status

The University of Chicago Medical Center /ID# 203216

Chicago, Illinois, United States

Site Status

Duplicate_NorthShore University HealthSystem /ID# 215583

Evanston, Illinois, United States

Site Status

Ingalls Memorial Hosp /ID# 203228

Harvey, Illinois, United States

Site Status

Joliet Oncology-Hematology Associates, LTD /ID# 203238

Joliet, Illinois, United States

Site Status

Goshen Center for Cancer Care /ID# 215584

Goshen, Indiana, United States

Site Status

Univ Kansas Med Ctr /ID# 216804

Kansas City, Kansas, United States

Site Status

Cancer Center of Kansas /ID# 203235

Wichita, Kansas, United States

Site Status

Duplicate_Baptist Health /ID# 203283

Lexington, Kentucky, United States

Site Status

Duplicate_Norton Cancer Institute - St Matthews /ID# 203284

Louisville, Kentucky, United States

Site Status

Central Maine Medical Center /ID# 216583

Lewiston, Maine, United States

Site Status

Massachusetts General Hospital /ID# 203215

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical Center /ID# 208124

Boston, Massachusetts, United States

Site Status

Dana-Farber Cancer Institute /ID# 203248

Boston, Massachusetts, United States

Site Status

Henry Ford Hospital /ID# 203220

Detroit, Michigan, United States

Site Status

Mayo Clinic - Rochester /ID# 215603

Rochester, Minnesota, United States

Site Status

Hattiesburg Clinic /ID# 227691

Hattiesburg, Mississippi, United States

Site Status

St. Lukes Cancer Institute /ID# 227697

Kansas City, Missouri, United States

Site Status

Washington University-School of Medicine /ID# 203217

St Louis, Missouri, United States

Site Status

Duplicate_Intermountain Health - St Vincent Regional Hospital - Cancer Centers o /ID# 203292

Billings, Montana, United States

Site Status

Duplicate_Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 203350

Lebanon, New Hampshire, United States

Site Status

Titan Health Partners LLC, d/b/a Astera Cancer Care /ID# 228868

East Brunswick, New Jersey, United States

Site Status

Atlantic Health System /ID# 203404

Morristown, New Jersey, United States

Site Status

Capital Health Medical Center /ID# 203403

Pennington, New Jersey, United States

Site Status

Overlook Medical Center /ID# 211160

Summit, New Jersey, United States

Site Status

University of New Mexico /ID# 208339

Albuquerque, New Mexico, United States

Site Status

Duplicate_Gabrail Cancer Center Research /ID# 216056

Canton, Ohio, United States

Site Status

Univ Hosp Cleveland /ID# 215648

Cleveland, Ohio, United States

Site Status

Mercy Cancer Center /ID# 231972

Elyria, Ohio, United States

Site Status

Mercy Research Mercy Clinic Oklahoma Communities, Inc. / OKC /ID# 230154

Oklahoma City, Oklahoma, United States

Site Status

Providence Cancer Center Oncology and Hematology Care - Westside Portland /ID# 203301

Portland, Oregon, United States

Site Status

Penn State University and Milton S. Hershey Medical Center /ID# 221844

Hershey, Pennsylvania, United States

Site Status

Duplicate_Allegheny General Hospital /ID# 215585

Pittsburgh, Pennsylvania, United States

Site Status

Veterans Healthcare System /ID# 215602

Pittsburgh, Pennsylvania, United States

Site Status

Thompson Cancer Survival Ctr /ID# 228874

Knoxville, Tennessee, United States

Site Status

Vanderbilt Ingram Cancer Center /ID# 203281

Nashville, Tennessee, United States

Site Status

Houston Methodist Hospital /ID# 213268

Houston, Texas, United States

Site Status

Baylor Scott & White Medical Center- Temple /ID# 216578

Temple, Texas, United States

Site Status

Virginia Cancer Specialists - Fairfax /ID# 203224

Fairfax, Virginia, United States

Site Status

Valley Medical Center /ID# 231459

Renton, Washington, United States

Site Status

University of Washington /ID# 206056

Seattle, Washington, United States

Site Status

Wisconsin Medical Center /ID# 210062

Milwaukee, Wisconsin, United States

Site Status

The Kinghorn Cancer Centre /ID# 207666

Darlinghurst, New South Wales, Australia

Site Status

Newcastle Private Hospital /ID# 206600

Lambton Heights, New South Wales, Australia

Site Status

The Tweed Hospital /ID# 206601

Tweed Heads, New South Wales, Australia

Site Status

Mater Misericordiae Limited /ID# 229639

South Brisbane, Queensland, Australia

Site Status

St John Of God Subiaco Hospital /ID# 226943

Subiaco, Western Australia, Australia

Site Status

Universitair Ziekenhuis Antwerpen /ID# 217430

Edegem, Antwerpen, Belgium

Site Status

Hospital La Louviere Site Jolimont - Helora /ID# 230586

La Louvière, Hainaut, Belgium

Site Status

Jessa Ziekenhuis /ID# 234047

Hasselt, Limburg, Belgium

Site Status

Vitaz /Id# 239966

Sint-Niklaas, Oost-Vlaanderen, Belgium

Site Status

Institut Jules Bordet /ID# 238614

Anderlecht, , Belgium

Site Status

AZ Maria Middelares /ID# 233474

Ghent, , Belgium

Site Status

AZ Groeninge /ID# 217431

Kortrijk, , Belgium

Site Status

Duplicate_CHU de Liege /ID# 230589

Liège, , Belgium

Site Status

UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 234048

Namur, , Belgium

Site Status

MHAT Dobrich /ID# 230074

Dobrich, , Bulgaria

Site Status

UMHAT Dr Georgi Stranski EAD /ID# 232024

Pleven, , Bulgaria

Site Status

Medical Center Nadezhda /ID# 230473

Sofia, , Bulgaria

Site Status

Acibadem City Clinic Tokuda University Hospital EAD /ID# 232010

Sofia, , Bulgaria

Site Status

Duplicate_Cross Cancer Institute /ID# 204540

Edmonton, Alberta, Canada

Site Status

Ottawa Hospital Research Institute /ID# 205579

Ottawa, Ontario, Canada

Site Status

University Health Network_Princess Margaret Cancer Centre /ID# 204423

Toronto, Ontario, Canada

Site Status

CISSS de la Monteregie /ID# 211356

Greenfield Park, Quebec, Canada

Site Status

Anhui Provincial Hospital /ID# 212096

Hefei, Anhui, China

Site Status

Anhui Provincial Cancer Hospital /ID# 239058

Hefei, Anhui, China

Site Status

Anhui Medical University - Anhui Chest Hospital /ID# 239048

Hefei, Anhui, China

Site Status

Beijing Cancer Hospital /ID# 210133

Beijing, Beijing Municipality, China

Site Status

Fujian Provincial Cancer Hospital /ID# 210808

Fuzhou, Fujian, China

Site Status

The First Affiliated Hospital Of Guangzhou Medical University /ID# 232261

Guangzhou, Guangdong, China

Site Status

Affiliated Cancer Hospital of Guangxi Medical University /ID# 231560

Nanning, Guangxi, China

Site Status

Affiliated Hospital of Hebei University /ID# 227262

Baoding, Hebei, China

Site Status

Harbin Medical University Cancer Hospital /Id# 231573

Harbin, Heilongjiang, China

Site Status

Henan Cancer Hospital /ID# 210961

Zhengzhou, Henan, China

Site Status

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 211119

Wuhan, Hubei, China

Site Status

The First People's Hospital of Changzhou /ID# 210787

Changzhou, Jiangsu, China

Site Status

Jilin Cancer Hospital /ID# 210563

Changchun, Jilin, China

Site Status

Shandong Cancer Hospital /ID# 231577

Jinan, Shandong, China

Site Status

Shanghai Chest Hospital /ID# 210930

Shanghai, Shanghai Municipality, China

Site Status

Evimed Clinic /ID# 216473

Chelyabinsk, , Russia

Site Status

Fudan University Cancer Hospital /ID# 210084

Shanghai, Shanghai Municipality, China

Site Status

West China Hospital, Sichuan University /ID# 210022

Chengdu, Sichuan, China

Site Status

The Affiliated Cancer Hospital of Xinjiang Medical University /ID# 227244

Ürümqi, Xinjiang, China

Site Status

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 211154

Hangzhou, Zhejiang, China

Site Status

Zhejiang Cancer hospital /ID# 210085

Hangzhou, Zhejiang, China

Site Status

Duplicate_Vseobecna fakultni nemocnice v Praze /ID# 229797

Prague, Praha 17, Czechia

Site Status

Multiscan s.r.o. /ID# 241926

Prague, , Czechia

Site Status

APHM - Hopital Nord /ID# 209854

Marseille, Bouches-du-Rhone, France

Site Status

Institut Bergonie /ID# 216207

Bordeaux, Gironde, France

Site Status

CHU Lille - Hôpital Albert Calmette /ID# 205105

Lille, Hauts-de-France, France

Site Status

Institut Curie /ID# 207046

Paris, Paris, France

Site Status

Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 216209

Bron, Rhone, France

Site Status

Centre Leon Berard /ID# 205107

Lyon, Rhone, France

Site Status

Centre Hosp Intercommunal de Creteil /ID# 227108

Créteil, Val-de-Marne, France

Site Status

Institut Gustave Roussy /ID# 205149

Villejuif, Val-de-Marne, France

Site Status

CHI Toulon-La Seyne sur Mer /ID# 230545

Toulon, Var, France

Site Status

CHU Strasbourg - Hopital Civil /ID# 208080

Strasbourg, , France

Site Status

Universitatsklinikum Mannheim /ID# 228798

Mannheim, Baden-Wurttemberg, Germany

Site Status

Gemeinschaftspraxis Dr. Heinrich und Prof. Bangerter /ID# 232052

Augsburg, Bavaria, Germany

Site Status

Universitaetsklinikum Giessen /ID# 231856

Giessen, Hesse, Germany

Site Status

Klinikum Kassel /ID# 205443

Kassel, Hesse, Germany

Site Status

Pius-Hospital Oldenburg /ID# 211615

Oldenburg, Lower Saxony, Germany

Site Status

Krankenhaus Martha-Maria Halle-Doelau /ID# 205442

Halle, Saxony-Anhalt, Germany

Site Status

Vivantes Klinikum Neukolln /ID# 205928

Berlin, , Germany

Site Status

Asklepios Fachkliniken Muenchen-Gauting /ID# 207789

Gauting, , Germany

Site Status

Evangelisches Krankenhaus Hamm /ID# 208043

Hamm, , Germany

Site Status

General Hospital of Chest Diseases of Athens SOTIRIA /ID# 205528

Athens, Attica, Greece

Site Status

Metropolitan Hospital /ID# 205529

Piraeus, Attica, Greece

Site Status

University General Hospital of Heraklion PA.G.N.I /ID# 205530

Heraklion, Crete, Greece

Site Status

Bioclinic Thessaloniki /ID# 227261

Thessaloniki, , Greece

Site Status

Euromedica General Clinic /ID# 227264

Thessaloniki, , Greece

Site Status

CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 204878

Encs, Borsod-Abauj Zemplen county, Hungary

Site Status

Torokbalinti Tudogyogyintezet /ID# 204883

Törökbálint, Pest County, Hungary

Site Status

Duplicate_Semmelweis Egyetem /ID# 204434

Budapest, , Hungary

Site Status

Duplicate_Veszprem Megyei Tudogyogyintez /ID# 213950

Farkasgyepű, , Hungary

Site Status

Matrai Gyogyintezet /ID# 204432

Mátraháza, , Hungary

Site Status

Cork University Hospital /ID# 205103

Wilton, Cork, Ireland

Site Status

Mater Misericordiae Univ Hospital /ID# 231466

Dublin, Dublin, Ireland

Site Status

St James Hospital /ID# 205104

Dublin, Dublin, Ireland

Site Status

St Vincents University Hospital /ID# 205102

Elm Park, Dublin, Ireland

Site Status

Meir Medical Center /ID# 204255

Kfar Saba, Central District, Israel

Site Status

Soroka University Medical Center /ID# 204898

Beersheba, Southern District, Israel

Site Status

The Chaim Sheba Medical Center /ID# 204254

Ramat Gan, Tel Aviv, Israel

Site Status

Rambam Health Care Campus /ID# 204866

Haifa, , Israel

Site Status

Rabin Medical Center /ID# 215322

Petah Tikva, , Israel

Site Status

Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 216153

Bologna, Emilia-Romagna, Italy

Site Status

Duplicate_Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS /ID# 205601

Meldola, Forlì-Cesena, Italy

Site Status

IRCCS Ospedale San Raffaele /ID# 226973

Milan, Milano, Italy

Site Status

Azienda Ospedaliera Universitaria Federico II /ID# 231948

Naples, Napoli, Italy

Site Status

Duplicate_IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Reg /ID# 227011

Rome, Roma, Italy

Site Status

Azienda Ospedaliera San Camillo Forlanini /ID# 205163

Rome, Roma, Italy

Site Status

Duplicate_A.O.U. San Luigi Gonzaga /ID# 204706

Orbassano, Torino, Italy

Site Status

L'Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialità San Giuseppe Mos /ID# 204707

Avellino, , Italy

Site Status

Azienda Ospedaliero-Universitaria di Parma /ID# 204983

Parma, , Italy

Site Status

Fondazione Policlinico Universitario Campus Bio-Medico /ID# 215918

Roma, , Italy

Site Status

Chukyo Hospital /ID# 244755

Nagoya, Aichi-ken, Japan

Site Status

Aichi Cancer Center Hospital /ID# 207790

Nagoya, Aichi-ken, Japan

Site Status

Hirosaki University Hospital /ID# 245023

Hirosaki-shi, Aomori, Japan

Site Status

Duplicate_Chiba University Hospital /ID# 232204

Chiba, Chiba, Japan

Site Status

Duplicate_National Hospital Organization Shikoku Cancer Center /ID# 232252

Matsuyama, Ehime, Japan

Site Status

Duplicate_National Hospital Organization Kyushu Cancer Center /ID# 206061

Fukuoka, Fukuoka, Japan

Site Status

Kurume University Hospital /ID# 227776

Kurume-shi, Fukuoka, Japan

Site Status

Chugoku Central Hospital /ID# 245022

Fukuyama, Hiroshima, Japan

Site Status

Hiroshima Citizens Hospital /ID# 218087

Hiroshima, Hiroshima, Japan

Site Status

Himeji Medical Center /ID# 227777

Himeji-shi, Hyōgo, Japan

Site Status

Kobe Minimally Invasive Cancer Center /ID# 248590

Kobe, Hyōgo, Japan

Site Status

Takarazuka City Hospital /ID# 245185

Takarazuka-shi, Hyōgo, Japan

Site Status

Yokohama Municipal Citizen's Hospital /ID# 248374

Yokohama, Kanagawa, Japan

Site Status

Duplicate_Kanagawa Cancer Center /ID# 205068

Yokohama, Kanagawa, Japan

Site Status

Matsusaka Municipal Hospital /ID# 230219

Matsusaka-shi, Mie-ken, Japan

Site Status

Sendai Kousei Hospital /ID# 216460

Sendai, Miyagi, Japan

Site Status

Niigata Cancer Center Hospital /ID# 216462

Niigata, Niigata, Japan

Site Status

Okayama University Hospital /ID# 227851

Okayama, Okayama-ken, Japan

Site Status

Osaka City General Hospital /ID# 233172

Osaka, Osaka, Japan

Site Status

Osaka International Cancer Institute /ID# 210735

Osaka, Osaka, Japan

Site Status

NHO Kinki Chuo Chest Medical Center /ID# 216461

Sakai-shi, Osaka, Japan

Site Status

Duplicate_Saitama Cancer Center /ID# 232508

Kitaadachi-gun, Saitama, Japan

Site Status

Fujieda Municipal General Hospital /ID# 248589

Fujieda-shi, Shizuoka, Japan

Site Status

Duplicate_Duplicate_Duplicate_Shizuoka Cancer Center /ID# 205065

Sunto-gun, Shizuoka, Japan

Site Status

National Cancer Center Hospital /ID# 205066

Chuo-ku, Tokyo, Japan

Site Status

Duplicate_The Cancer Institute Hospital Of JFCR /ID# 216463

Koto-ku, Tokyo, Japan

Site Status

Yamaguchi - Ube Medical Center /ID# 227778

Ube-shi, Yamaguchi, Japan

Site Status

Ziekenhuis St. Jansdal /ID# 216658

Harderwijk, Gelderland, Netherlands

Site Status

Antoni van Leeuwenhoek /ID# 216657

Amsterdam, North Holland, Netherlands

Site Status

Meander Medisch Centrum /ID# 217756

Amersfoort, Utrecht, Netherlands

Site Status

Med Polonia Sp. z o. o. /ID# 229908

Poznan, Greater Poland Voivodeship, Poland

Site Status

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 230595

Warsaw, Masovian Voivodeship, Poland

Site Status

Wojewodzki Szpital im. Sw. Ojca Pio /ID# 231960

Przemyśl, Podkarpackie Voivodeship, Poland

Site Status

Dom Lekarski S.A. /ID# 231479

Szczecin, West Pomeranian Voivodeship, Poland

Site Status

Duplicate_Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej /ID# 231476

Lodz, Łódź Voivodeship, Poland

Site Status

VA Caribbean Healthcare System /ID# 206336

San Juan, , Puerto Rico

Site Status

Puerto Rico Hematology Oncolog /ID# 206337

San Juan, , Puerto Rico

Site Status

Institutul Oncologic Prof Dr. Ion Chiricuta Cluj Napoca /ID# 206320

Cluj-Napoca, Cluj, Romania

Site Status

S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 227623

Craiova, Dolj, Romania

Site Status

Spitalul Municipal Ploiesti /ID# 229097

Ploieşti, Prahova, Romania

Site Status

Oncomed SRL /ID# 205616

Timișoara, Timiș County, Romania

Site Status

Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti /ID# 227216

Bucharest, , Romania

Site Status

Spitalul Clinic Coltea /ID# 227241

Bucharest, , Romania

Site Status

S.C. Gral Medical Srl /Id# 227215

Bucharest, , Romania

Site Status

Krasnoyarsk Regional Clinical Oncology Dispensary n.a. A.I. Kryzhanovsky /ID# 232065

Krasnoyarsk, Krasnoyarsk Krai, Russia

Site Status

LLC Medical Center /ID# 212397

Novosibirsk, Novosibirsk Oblast, Russia

Site Status

Clinical Oncology Dispensary of Omsk /ID# 239313

Omsk, Omsk Oblast, Russia

Site Status

St. Petersburg scientific center for specialized medical care (oncological) /ID# 206405

Saint Petersburg, Sankt-Peterburg, Russia

Site Status

Newclinic Medical Center /ID# 216262

Pyatigorsk, Stavropol Kray, Russia

Site Status

Republican Clinical Oncology Dispensary /ID# 206463

Kazan', Tatarstan, Respublika, Russia

Site Status

Regional Children's Clinical Hospital of Volgograd /ID# 206520

Volgograd, Volgograd Oblast, Russia

Site Status

Arkhangelsk Clinical Oncology Dispensary /ID# 216418

Arkhangelsk, , Russia

Site Status

Kostroma region oncology center /ID# 231317

Kostroma, , Russia

Site Status

Univercity Headache Clynic,LTD /ID# 212080

Moscow, , Russia

Site Status

VitaMed LLC /ID# 228957

Moscow, , Russia

Site Status

National Medical Research Radiological Centre /ID# 231263

Obninsk, , Russia

Site Status

Euromedservice /ID# 206390

Pushkin, , Russia

Site Status

Center of Palliative Medicine De Vita /ID# 212900

Saint Petersburg, , Russia

Site Status

National Cancer Center /ID# 204241

Goyang-si, Gyeonggido, South Korea

Site Status

Duplicate_Seoul National University Bundang Hospital /ID# 204237

Seongnam, Gyeonggido, South Korea

Site Status

The Catholic University Of Korea St. Vincent's Hospital /ID# 229647

Suwon, Gyeonggido, South Korea

Site Status

Pusan National University Yangsan Hospital /ID# 233871

Yangsan, Gyeongsangnam-do, South Korea

Site Status

Inha University Hospital /ID# 234206

Incheon, Incheon Gwang Yeogsi, South Korea

Site Status

Chonnam National University Hwasun Hospital /ID# 206951

Hwasun-gun, Jeonranamdo, South Korea

Site Status

Duplicate_Chungbuk National Univ Hosp /ID# 205680

Cheongju-si, North Chungcheong, South Korea

Site Status

Asan Medical Center /ID# 204236

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Samsung Medical Center /ID# 227083

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Duplicate_Hospital Clínico Universitario de Santiago-CHUS /ID# 204367

Santiago de Compostela, A Coruna, Spain

Site Status

Instituto Catalan de Oncologia (ICO) Badalona /ID# 216106

Badalona, Barcelona, Spain

Site Status

CHU Insular-Materno Infantil /ID# 232362

Las Palmas de Gran Canaria, Las Palmas, Spain

Site Status

Hospital Universitario Fundacion Alcorcon /ID# 232361

Alcorcón, Madrid, Spain

Site Status

Hospital Nuestra Senora de Sonsoles /ID# 232367

Ávila, , Spain

Site Status

Hospital Universitario Dexeus - Grupo Quironsalud /ID# 232368

Barcelona, , Spain

Site Status

Hospital Universitario Vall de Hebron /ID# 206997

Barcelona, , Spain

Site Status

Hospital Universitario Ramon y Cajal /ID# 203922

Madrid, , Spain

Site Status

Hospital Universitario HM Sanchinarro /ID# 203913

Madrid, , Spain

Site Status

Hospital Regional Universitario de Malaga /ID# 216081

Málaga, , Spain

Site Status

Hospital Universitario Virgen Macarena /ID# 230998

Seville, , Spain

Site Status

Hospital Universitario Virgen del Rocio /ID# 216058

Seville, , Spain

Site Status

Hospital Universitario y Politecnico La Fe /ID# 203862

Valencia, , Spain

Site Status

University Hospital Basel /ID# 230977

Basel Town, Canton of Basel-City, Switzerland

Site Status

KSW Kantonsspital Winterthur /ID# 231284

Winterthur, Canton of Zurich, Switzerland

Site Status

Duplicate_Kaohsiung Chang Gung Memorial Hospital /ID# 205423

Kaohsiung City, Kaohsiung, Taiwan

Site Status

National Taiwan University Hospital /ID# 205100

Taipei City, Taipei, Taiwan

Site Status

Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 205309

Chiayi City, , Taiwan

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 205831

Kaohsiung City, , Taiwan

Site Status

Taipei Medical University Shuang Ho Hospital /ID# 215356

New Taipei City, , Taiwan

Site Status

Taichung Veterans General Hospital /ID# 205308

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital /ID# 205307

Tainan City, , Taiwan

Site Status

Koo Foundation Sun Yat-Sen Cancer Center /ID# 227336

Taipei, , Taiwan

Site Status

Linkou Chang Gung Memorial Hospital /ID# 205424

Taoyuan, , Taiwan

Site Status

Adana Sehir Egitim ve Arastirma Hastanesi /ID# 206000

Adana, , Turkey (Türkiye)

Site Status

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 205243

Ankara, , Turkey (Türkiye)

Site Status

Gazi University Medical Faculty /ID# 239816

Ankara, , Turkey (Türkiye)

Site Status

Akdeniz Universitesi Tip Fakul /ID# 205238

Antalya, , Turkey (Türkiye)

Site Status

Trakya University Medical Facu /ID# 205242

Edirne, Istanbul, , Turkey (Türkiye)

Site Status

Prof. Dr. Suleyman Yalcın Sehir Hastanesi /ID# 215082

Istanbul, , Turkey (Türkiye)

Site Status

Dr. Suat Seren Gogus Has /ID# 215083

Izmir, , Turkey (Türkiye)

Site Status

Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 239889

London, Greater London, United Kingdom

Site Status

University College London Hospital /ID# 231467

London, Greater London, United Kingdom

Site Status

Nottingham City Hospital /ID# 231224

Nottingham, Nottinghamshire, United Kingdom

Site Status

Oxford University Hospitals NHS Foundation Trust /ID# 205890

Oxford, Oxfordshire, United Kingdom

Site Status

University Hospitals Birmingham NHS Foundation Trust /ID# 206209

Birmingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Bulgaria Canada China Czechia France Germany Greece Hungary Ireland Israel Italy Japan Netherlands Poland Puerto Rico Romania Russia South Korea Spain Switzerland Taiwan Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6.

Reference Type DERIVED
PMID: 38843488 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-507902-15-00

Identifier Type: OTHER

Identifier Source: secondary_id

M14-239

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.